February 2, 2021 5:40pm

However, multiple highs will loosen the share pricing ownership strings

Pre-open indication results: 9 HITs and 2 MISS – profited by selling into strength and a surprise offering

News: Pluristem (PSTI) announces $30 M Registered Direct Offering priced at $6.30 … https://www.regmedinvestors.com/articles/11750

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting! Numbers based facts speak better then opinion as I see answers in numbers

Keeping “tabs” on sector movements, are you ready - sector earnings LPS (loss-per-share) season is about to begin?


The Dow closed UP +475.57 points (+1.57%); the S&P closed UP +52.45 points (+1.39%) while the Nasdaq closed UP +209.38 points (+1.56%)



Indexes jumped on Tuesday, building on a strong rally from the previous session – be ready for the decline.


RegMed Investors’ (RMi) pre-open: “volatility ain’t over ‘til the short positions decline and earnings’ LPS (loss-per-share) release” … https://www.regmedinvestors.com/articles/11749


Pre-open indication results:  9 HITs <Maintaining SELL: Biostage (BSTG -$0.00 with 205 shares traded); SELL: Editas Medicine (EDIT +$2.78), Homology Medicine (FIXX +$0.59), Vericel (VCEL +$0.70): SELL into Strength: Athersys (ATHX +$0.03);  Maintain BUY: Global Blood Therapeutics (GBT +$0.04); SELL: Caladrius Biosciences (CLBS -$0.04); BUY: CRISPR Therapeutics (CRSP +$2.47); Maintain BUY: Ionis Pharmaceuticals (IONS +$2.25) and 2 MISS <SELL: bluebird bio (BLUE +$0.67): Pluristem (PSTI -$0.93 – surprise offering)


Sentiment and COVID-19 infections:

Finally, Biden administration announces direct vaccine shipments to pharmacies – next week; will our primary care doctors be next?

Moderna (MRNA) wants to put more vaccine in each vial as supply challenge evolves as the biotech wants to put 15 doses of its vaccine into each vial, rather than 10, as the pinch point in the distribution process has moved away from administering injections.

Infection cases <Million>: never to forget …

  • Tuesday 26.32 M cases,
  • Tuesday’s death rate totaled 443,774 <Johns Hopkins University>


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Tuesday opened positive at 21/12 and 2 flats, stayed positive at the mid-day to 22/10 and 3 flats, closing positive at 25/7, 2 flat and 1 acquired;
  • Monday opened positive at 27/7 and 1 flat, stayed positive at the mid-day to 27/7 and 1 flat, closing positive at 22/11, 1 flat and 1 acquired;


Key metrics:

  • Sector volume was LOW with 10 of the 25-upside having higher than the 3-month average volume with the increased volume of 2 of 7-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 25-upside were +0.08% (GBT) to +9.93% (NTLA) while the 7-downside ranges from -0.47% (BLCM) to-12.47% (PSTI);


There are clear winners — and losers — heading into the first month of 2021.

All-time high:

  • The XBI reached an all-time high of 161.68

Jumping with share pricing momentum:

  • Intellia Therapeutics (NTLA), Ultragenyx (RARE), Alnylam Pharmaceuticals (ALNY), Fate Therapeutics (FATE), Editas Therapeutics (EDIT) to name 5 of the 25 inclining of the 35 covered

Hammered in today’s market:

  • Sage Therapeutics (SAGE), Pluristem (PSTI), Precigen (PGEN), Mesoblast (MESO), Caladrius Biosciences (CLBS) to name 5 of the 7 declining of the 35 covered


Tuesday’s (10 of 25) incliners:

  • Ultragenyx (RARE +$7.52 after Monday’s +$7.04);
  • Intellia Therapeutics (NTLA +$6.37 after Monday’s +$1.53);
  • Alnylam Pharmaceuticals (ALNY +$4.80 after Monday’s -$1.23);
  • Fate Therapeutics (FATE +$4.83 after Monday’s +$2.53);
  • Editas Medicine (EDIT +$2.78 after Monday’s +$1.54);
  • CRISPR Therapeutics (CRSP +$2.47 after Monday’s -$0.02);
  • Ionis Pharmaceuticals (IONS +$2.25 after Monday’s -$1.10);
  • Regenxbio (RGNX +$2.00 after Monday’s +$1.87);
  • BioLife Solutions (BLFS +$1.57 after Monday’s +$1.67);
  • Adverum Biotechnologies (ADVM +$0.90);

Tuesday’s (7 of 7) decliners:

  • Sage Therapeutics (SAGE -$3.32 after Monday’s +$2.01);
  • Pluristem (PSTI -$0.93 after an RDO offering announced);
  • Precigen (PGEN -$0.86 after Monday’s -$0.03);
  • Mesoblast (MESO -$010);
  • Caladrius BioSciences (CLBS -$0.04 after Monday’s -$0.04);
  • Verastem (VSTM -$0.02);
  • Bellicum Pharmaceuticals (BLCM -$0.02 after Monday’s -$0.42);

Closing 2 – Biostage (BSTG) and ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML – acquired)



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +1.11% and XBI closed up +2.27%
  • Monday, the IBB closed up +1.28% and XBI closed up +4.41%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up -4.68 points or -15.48% at 25.56
  • Monday was down -2.85 points or -8.61% at 30.24

Upside volume:

  • Tuesday: 10 out of the 25-upside had higher than the 3-month average volume;
  • Monday: 2 out of the 22-upside had higher than the 3-month average volume;

Downside volume:

  • Tuesday: 2 out of the 7-downside had higher than the 3-month average volume;
  • Monday: 2 out of the 11-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Tuesday’s percentage (%) of the 25-upside were +0.08% (GBT) to +9.93% (NTLA) while the 7-downside ranges from -0.47% (BLCM) to-12.47% (PSTI);
  • Monday’s percentage (%) of the22 -upside were +0.16% (ADVM) to +26.10% (ATHX) while the 11-downside ranges from -0.01% (CRSP) to -9.03% (BLCM);


February, the 2nd month of Q1 … a visual review identifies the range of sector volatility

Tuesday closed positive with 25 advancers, 7 decliners, 2 flats and 1 acquired

Monday (2/1) closed positive with 22 advancers, 11 decliners, 1 flat and 1 acquired


The Bottom Line: As new highs evolve, so won’t the declines as electronic trading reap profits before earnings’ season appears.

I believe there is a tone deafness in “our’ universe of RegMed, stem, cell and gene therapy equities.

Let’s NOT forget, it is a new tax year thus, a cut back of some (I say many) gains in the sector before the release of Q4 and FY20 “earnings” i.e., LPS (loss-per-share)!

Forewarned … earnings LPS (loss-per-share) season is coming quickly – my advice, trim and skim!!


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.